Astellas’ ambitious innovation and committed collaboration support new research on investigational and approved therapies in hard-to-treat cancers
TOKYO, May 17, 2021 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) will share new data across its oncology portfolio during the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting from June 4-8, 2021. Covering three approved treatments and one investigational therapy, the 12 Astellas-sponsored abstracts underscore the company’s commitment to advancing treatment options for difficult-to-treat cancers, including bladder, prostate and gastric/gastroesophageal junction (GEJ) cancers, as well as acute myeloid leukemia (AML).
“While oncology has seen incredible advancements over the last decade, there are still many patients whose disease has few or no effective treatments. Astellas is determined to change that reality,” said Andrew Krivoshik, M.D., Ph.D., Astellas Senior Vice President and Oncology Therapeutic Area Head. “Our data suggest that progress is possible, and we are committed to working with physicians, patients and others in the cancer community to change the course of hard-to-treat forms of cancer.”
“The latest investigational research supported by Astellas reflects our commitment to understanding unmet needs in cancer care and our mission to turn innovative science into treatments that are truly valued by patients and healthcare professionals,” said Erhan Berrak, M.D., Astellas Vice President of Medical Affairs, Oncology. “For example, research to be presented at ASCO includes a closer look at real-world treatment patterns in several clinical states of advanced prostate cancer, including the use of advanced treatments across racial groups – a topic closely aligned with the ASCO 2021 theme of equity.”
Astellas will share data across its portfolio and investigational therapies, with highlights including:
- Quality of life results from the Phase 3 EV-301 trial of enfortumab vedotin (EV) and an updated analysis of efficacy and safety data from EV-201 cohort 2 of EV; updated durability and long-term outcomes from the EV-103 clinical trial of EV and pembrolizumab – all in advanced types of urothelial cancer
- Research on racial disparities in advanced prostate cancer treatment, as well as real-world treatment patterns for patients with advanced prostate cancer
- Follow-up data from the Phase 3 ADMIRAL trial evaluating gilteritinib in patients with relapsed or refractory (resistant to treatment) AML with a FLT3 mutation
- Data from the Phase 2 study of zolbetuximab plus mFOLFOX6 in claudin 18.2-positive (CLDN18.2+) locally advanced or metastatic gastric or GEJ adenocarcinoma
Astellas Presentations at ASCO21
Enfortumab Vedotin
| Presentation Title | Lead Author | Presentation Details |
| Enfortumab vedotin in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer who received prior PD-1/PD-L1 inhibitors: An updated analysis of EV-201 Cohort 2 | B. McGregor | Type: Poster Abstract Number: 4524 |
| Study EV-103: Update on durability results and long-term outcome of enfortumab vedotin + pembrolizumab in first line locally advanced or metastatic urothelial carcinoma (la/mUC) | T. Friedlander | Type: Poster Abstract Number: 4528 |
| Quality of life, functioning, and symptoms in patients with previously treated locally advanced or metastatic urothelial carcinoma from EV-301: A randomized phase 3 trial of enfortumab vedotin vs chemotherapy | R. Mamtani | Type: Poster Abstract Number: 4539 |
| KEYNOTE-B15/EV-304: Randomized phase 3 study of perioperative enfortumab vedotin plus pembrolizumab versus chemotherapy in cisplatin-eligible patients with muscle-invasive bladder cancer (MIBC) | C. Hoimes | Type: Poster Abstract Number: TPS4587 |
| Opioid use in locally advanced or metastatic urothelial carcinoma patients and matched non-cancer controls | S. Grewal | Type: Publication Only Abstract Number: e16517 |
Enzalutamide
| Presentation Title | Lead Author | Presentation Details |
| The efficacy of enzalutamide (ENZA) plus androgen deprivation therapy (ADT) on bone oligometastatic hormone-sensitive prostate cancer: A post hoc analysis of ARCHES | A. Armstrong | Type: Poster Abstract Number: 5071 |
| Real world first-line (1L) treatment patterns in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) in a U.S. health insurance database | U. Swami | Type: Poster Abstract Number: 5072 |
| Real-world utilization of advanced therapies and racial disparity among patients with metastatic castration-sensitive prostate cancer (mCSPC): A Medicare database analysis | S. Freedland | Type: Poster Abstract Number: 5073 |
| Real-world treatment patterns among patients diagnosed with metastatic castration-sensitive prostate cancer (mCSPC) in community oncology settings | D. George |
Type: Poster |
Gilteritinib
| Presentation Title | Lead Author | Presentation Details |
| Follow-up of patients with FLT3-mutated R/R AML in the phase 3 ADMIRAL trial | A. Perl | Type: Poster Abstract Number: 7013 |
Zolbetuximab
| Presentation Title | Lead Author | Presentation Details |
| Phase 2 study of zolbetuximab plus mFOLFOX6 in claudin 18.2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ): ILUSTRO cohort 2 | S. Klempner | Type: Publication Only Abstract Number: e16063 |
| Effect of ethnicity and chemotherapy (mFOLFOX6) on zolbetuximab pharmacokinetics in patients with claudin 18.2+ locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ) | K. Lee | Type: Publication Only Abstract Number: e16078 |
The ASCO 2021 Annual Meeting abstracts are available at the ASCO Meeting Library.
Click below for a copy of the full press release
